On September 17, 2019, the combination therapy of Eisai’s LENVIMA (lenvatinib) and Merck’s KEYTRUDA (pembrolizumab) for the treatment of advanced endometrial carcinoma received simultaneous approvals by Health Canada, the U.S. Food and Drug Administration (FDA), and the Australian Therapeutic Goods Administration.
The joint decision by all three regulatory authorities was the first of its kind and a direct result of the collaborative review process under Project Orbis, a new initiative of the FDA Oncology Center of Excellence. Project Orbis provides the framework for concurrent submission and review of oncology products among international partners despite regulatory divergence, with the goal of facilitating early patient access to innovative oncology products and promoting greater uniformity in the standards of treatment.
In a news release announcing the first action under Project Orbis, the FDA indicated that other countries in addition to Canada and Australia may be involved in future collaborative reviews.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Federal Court of Appeal restores Minister of Health’s decision to grant RUZURGI NOC despite FIRDAPSE data protection
The Federal Court found that subsection C.08.004.1(3) of the Food and Drug Regulations applied to prevent the Minister from issuing an NOC in view of the data protection granted to FIRDAPSE, a drug co...Read More -
Consultation open on Health Canada’s proposal on agile licensing for drugs and medical devices
On December 17, 2022, the proposed amendments to both regulations were published for consultation: Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing).Read More -
Certificate of Supplementary Protection filing fee increase effective April 1, 2023
On April 1, 2023, the fee for filing a Certificate of Supplementary Protection (CSP) will increase from $9,952 to $10,152 in accordance with subsection 9(1) of the Certificate of Supplementary Protect...Read More